相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant Treatment in Pancreatic Cancer
Atsushi Oba et al.
FRONTIERS IN ONCOLOGY (2020)
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
Changhoon Yoo et al.
BRITISH JOURNAL OF CANCER (2020)
Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals
Louis Allott et al.
MOLECULAR PHARMACEUTICS (2020)
Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes
M. W. Steen et al.
BJS OPEN (2020)
[18F] Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction
T. Harustiak et al.
BRITISH JOURNAL OF SURGERY (2018)
PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study
Entesar Dalah et al.
TRANSLATIONAL ONCOLOGY (2018)
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy
Eric A. Mellon et al.
ACTA ONCOLOGICA (2017)
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma
Mathilde Wagner et al.
EUROPEAN RADIOLOGY (2017)
Pancreatic Adenocarcinoma, Version 2.2017
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma A systematic review and meta-analysis
Dongyong Zhu et al.
MEDICINE (2017)
Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism
Tao Shan et al.
ONCOLOGY REPORTS (2017)
FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
H. Akita et al.
EJSO (2017)
18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction
Sara Sheikhbahaei et al.
NUCLEAR MEDICINE COMMUNICATIONS (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
Cristina R. Ferrone et al.
ANNALS OF SURGERY (2015)
Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma
Moshim Kukar et al.
JAMA SURGERY (2015)
Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy
Hye Jin Choi et al.
YONSEI MEDICAL JOURNAL (2014)
Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence
Akinori Asagi et al.
PANCREAS (2013)
Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Pathologic Response to Preoperative Chemoradiation Therapy in Patients With Resectable T3 Pancreatic Cancer
Hirotada Kittaka et al.
WORLD JOURNAL OF SURGERY (2013)
Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation Long-Term Results of a Prospective Trial (National Clinical Trial 00254683)
Rodrigo Oliva Perez et al.
CANCER (2012)
Differential Expression of Metabolic Genes in Tumor and Stromal Components of Primary and Metastatic Loci in Pancreatic Adenocarcinoma
Nina V. Chaika et al.
PLOS ONE (2012)
Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy
Erkan Topkan et al.
BMC GASTROENTEROLOGY (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
18FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
Devin Schellenberg et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT
Robert Rosenberg et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity Results of a Prospective Phase II Trial
Stefan Heinrich et al.
ANNALS OF SURGERY (2008)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Value of complete metabolic response by 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy
Min Kyoung Kim et al.
EUROPEAN JOURNAL OF CANCER (2007)
Role of positron emission tomography with 2-deoxy-2-[F-18]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer
M Yoshioka et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Clinical applications of PET in oncology
EM Rohren et al.
RADIOLOGY (2004)
分享论文
